Maurice van Tilburg – Glimne

Chairman 0001731122-24-001606 Maurice van Tilburg has held several senior positions in the Financial Services industry and Tech enterprises combining general management, technology, operational service delivery, financial management, audit and product development. He is also an awarded artist that combines leadership roles in the industry with a successful series of art concepts. Mr. van Tilburg currently…

David Weinstein

Director & Chief Executive Officer (CEO) Mr. Weinstein has thirty years of experience with U.S. securities and investment banking firms. He has been a Managing Partner of Investment Banking since 2005. Prior to joining Renovaro Inc., Mr. Weinstein was Director of Dawson James Securitiesand, prior to that, Director of Research for National Securities Corporation and,…

Douglas W. Calder

Director Since 2015, Mr. Calder has served as president and a director of Vycellix, Inc and its subsidiaries and affiliates. He has also served as a member of the board of directors for Zevra Therapeutics, Inc. (NASDAQ: ZVRA) since April 2023; member of the board of directors for NextGenNK since June 2019; member of the…

Mark Collins, Phd

Director Dr. Collins has dedicated his 40-year career to leveraging computers in drug discovery, blending biology, AI, and software. He has played key roles in biotech startups, large Pharma, and tech companies, leading several to successful exits. Dr. Collins is currently the Chief Scientific Officer at UndauntedBio Inc., where he has served since 2022, a…

James A. McNulty

Director Mr. McNulty serves as CFO for MIRALOGX, LLC, a privately held incubator which develops and licenses pharmaceutical intellectual property to private and public entities. Mr. McNulty is currently Interim CFO for Inhibitor Therapeutics, Inc. (OTCQB: INTI), where he has served since 2022. After leaving public accounting in 1998 after a 26-year career in Tampa…

Simon Tarsh

Interim Chief Financial Officer On March 11, 2024, the Company appointed Simon Tarsh, age 63, as Interim Chief Financial Officer of the Company. Mr. Tarsh most recently served at Deloitte Consulting LLP (“Deloitte”), where he was last a Senior Managing Director in the Finance and Enterprise Performance Practice, and served global clients since 2007. He…

Henk Viëtor (MD, PHD)

Managing Director & President Henk is a medical doctor specialized in Immunology, Transfusion Medicine and ClinicalGenetics. He became involved in the Life Sciences industry in 2000 and has been an active entrepreneur founding more than 35 Life Sciences companies including drug discovery, medical devices, service providers, but primarily in diagnostics including SkylkineDiagnostics, Mendus and DC4U. Henk has been involved in numerous public-private-partnerships, and was on the supervisory board of CTMM, Lygature and Skyline Diagnostics and is advisor for Technobis.

Frank Van Asch

Chief Technology Officer (CTO) Frank holds a Postgraduate Degree in Business Analytics and Data Science. He is multi-disciplinary skilled in Data Science and Data Mining with a track record in FinTech, HighTech and BioTech. Domain knowledge and experience of existing and emerging technology and platforms especially but not limited to data science, advanced analytics and…

Rhys Tombling

Finance Director (FD) Rhys has over 10years’ experience in the private sector, specializing in financial control and operations for start-up / scale-up’s sized FMCG & SaaS companies. He is an experienced chartered accountant, having specialised in financial audits, in IFRS, UK, US and Dutch GAAP. He also has extensive Big 4 experience in valuations, real-estate…